Previous Article | Next Article 
J Virol, June 1998, p. 4940-4949, Vol. 72, No. 6
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus Type 1 Glycoprotein B Requires
a Cysteine Residue at Position 633 for Folding, Processing, and
Incorporation into Mature Infectious Virus Particles
Sylvie
Laquerre,
Dina B.
Anderson,
Rafaela
Argnani,
and
Joseph C.
Glorioso*
Department of Molecular Genetics and
Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania
15261
Received 1 December 1997/Accepted 11 March 1998
 |
ABSTRACT |
Herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) resides in
the virus envelope in an oligomeric form and plays an essential role in
virus entry into susceptible host cells. The oligomerizing domain is a
movable element consisting of amino acids 626 to 653 in the gB external
domain. This domain contains a single cysteine residue at position 633 (Cys-633) that is predicted to form an intramolecular disulfide bridge
with Cys-596. In this study, we examined gB oligomerization,
processing, and incorporation into mature virus during infection
by two mutant viruses in which either the gB Cys-633
[KgB(C633S)] or both Cys-633 and Cys-596
[KgB(C596S/C633S)] residues were mutated to
serine. The result of immunofluorescence studies and analyses of
released virus particles showed that the mutant gB molecules were not
transported to the cell surface or incorporated into mature virus
envelopes and thus infectious virus was not produced.
Immunoprecipitation studies revealed that the mutant gB molecules were
in an oligomeric configuration and that these mutants produced
hetero-oligomers with a truncated form of gB consisting of residues 1 to 43 and 595 to 904, the latter containing the oligomerization domain.
Pulse-chase experiments in combination with endoglycosidase H treatment
determined that the mutant molecules were improperly processed, having
been retained in the endoplasmic reticulum (ER).
Coimmunoprecipitation experiments revealed that the cysteine mutations
resulted in gB misfolding and retention by the molecular chaperones
calnexin, calreticulin, and Grp78 in the ER. The altered conformation
of the gB mutant glycoproteins was directly detected by a reduction in
monoclonal antibody recognition of two previously defined distinct
antigenic sites located within residues 381 to 441 and 595 to 737. The
misfolded molecules were not transported to the cell surface as
hetero-oligomers with wild-type gB, suggesting that the
conformational change could not be corrected by intermolecular
interactions with the wild-type molecule. Together, these experiments
confirmed that a disulfide bridge involving Cys-633 and Cys-596 is not
essential for oligomerization but rather is required for proper folding
and maintenance of a gB domain essential to complete posttranslational
modification, transport, and incorporation into mature virus particles.
 |
INTRODUCTION |
Herpes simplex virus type 1 (HSV-1)
encodes at least 11 glycoproteins, 4 of which, glycoprotein B (gB), gD,
gH, and gL, are essential for virus attachment and entry in cell
culture (7, 9, 17, 29, 35). gB is among the most highly
conserved herpesvirus structural components, suggesting a common and
essential role in the life cycle of the Herpesviridae
(1, 40). gB is expressed as an early gene product that
persists following viral DNA synthesis, indicating that it is a member
of the
1 temporal class of genes (for a review, see reference
44). Molecular genetic studies of the functional
domains of gB have revealed that it contains structures involved in
controlling or defining the rate of virus entry, oligomer formation,
temperature-dependent stability, nuclear membrane localization,
antigenic sites, glycosylation, membrane anchorage, syncytial plaque
formation, and binding to the heparan sulfate receptor (4, 10, 11,
13, 15, 19, 24, 26, 36, 38, 43). Despite these detailed studies, unanswered questions remain regarding gB function, processing, and
incorporation into mature virions. For example, the molecular events
leading to the incorporation of gB into mature virus envelopes and the
mechanism through which gB cooperates with other viral envelope
components in the process of virus penetration continue to elude our
full understanding.
The gB structural gene sequence encodes 904 amino acids (6).
Biochemical analysis of gB has demonstrated that it contains a
30-residue N-terminal signal sequence that is cleaved during processing, a 697-residue external domain, a 68-residue transmembrane domain that is predicted to span the membrane three times, and a
109-residue cytoplasmic domain (6, 8, 12, 40). The molecule
forms minimally a homodimer during or soon after the process of
translation and is subsequently glycosylated through a series of
successive stages in the rough endoplasmic reticulum (ER) involving
carbohydrate addition to six consensus sites for N-linked glycosylation
(10, 11, 32). gB is further processed in the Golgi complex
and is transported to the cell surface of infected cells. Inhibitors of
Golgi processing (e.g., monensin) do not block functional gB
incorporation into cellular infectious virus particles (31).
The pathway for gB insertion into the virus envelope is thought to
involve diffusion or active transport of immature gB to the inner
nuclear membrane where it is initially acquired, along with the other
envelope glycoproteins during the process of virion budding (13,
20, 21, 47). At this point, two different pathways are proposed.
First, the immature envelope glycoproteins are transported to the Golgi
complex, where the precursor glycoproteins are modified in situ as the
enveloped particle moves through the Golgi compartment (31,
47). Alternatively, a second model for viral egress involves
fusion of the membrane acquired at the inner nuclear membrane with the
ER membrane (outer nuclear membrane), releasing nucleocapsids into the
cytoplasm which are subsequently reenveloped with Golgi-derived
vacuoles containing processed glycoproteins (41, 45).
HSV-1 gB contains 10 cysteine residues which are highly conserved among
the gB homologs of different herpesviruses, suggesting a critical role
for these cysteines in organizing the three-dimensional structure into
stable functional domains (42). Recently, the disulfide
bridges among the cysteine residues of HSV-2 gB were analyzed by
microsequencing of high-pressure liquid chromatography-purified tryptic
peptides in which disulfide bonds were shown to form between cysteines
1 and 8, 2 and 7, 5 and 6, and 9 and 10 (39). A similar pattern of disulfide bond formation is likely to occur in HSV-1-encoded gB, in view of the high degree of sequence conservation between type 1 and type 2 gB (39). The functional form of gB is an oligomer (8), and we recently reported that oligomer formation
required a 28-amino-acid movable domain consisting of residues 626 to
653 (34). Because cysteine 10 was located within this domain
at residue 633, it was substituted for serine at this position to explore the possibility that the disulfide bridge formed with cysteine
9 (residue 596) might be essential to facilitating the interactions
leading to oligomerization. Although oligomerization was reduced within
this gB truncated molecule, the domains were functional in the absence
of one or both of these cysteine residues (34). Whether the
full-length cysteine mutant forms of gB would oligomerize during
infection remained to be determined.
To further explore the role of Cys-633 and Cys-596 in gB full-length
function and infectious particle production, mutant viruses altered in
one or both of these gB residues were studied in cell culture
infections. The results of this investigation showed that mutant gB
molecules in which serine was substituted for Cys-633 or Cys-633 and
Cys-596 were not found in mature virus particles despite their ability
to form oligomers. Further analysis of the processing and trafficking
of the mutant gB forms demonstrated that they were incompletely
processed and remained bound to calnexin, Grp78, and calreticulin, a
complex of chaperone molecules for HSV glycoproteins, during processing
in the ER. These findings demonstrated that the disulfide bridge formed
between cysteines 9 and 10 is essential for proper folding of gB, a
prerequisite to gB processing and incorporation into mature virions.
 |
MATERIALS AND METHODS |
Cells and viruses.
Vero cells were obtained from the
American Type Culture Collection (Rockville, Md.). A Vero cell line
stably transfected with the HSV-1 genes encoding gB and ICP 18.5 (A1
[46]) (kindly provided by Fred L. Homa, Upjohn,
Kalamazoo, Mich.) was used to propagate a mutant virus, K
4BX,
deleted for both essential genes (16). K
4BX virus was
also used as a gB null virus when propagated on a Vero derivative cell
line stably transfected with the ICP 18.5 gene (C1
[46]). A Vero cell line stably transfected with the HSV-1 gene encoding gB (D6 [9]) was used to propagate
and determine the titers of the gB mutant viruses KgB(C633S) and
KgB(C596S/C633S). The cell lines were maintained at 37°C in
Dulbecco's modified essential medium (Gibco-BRL, Grand Island, N.Y.)
supplemented with 10% fetal bovine serum.
Construction of mutant gB plasmids.
Previously, nucleotide
sequences encoding a cysteine residue at position 633 of a gB molecule
were substituted for nucleotides encoding a serine residue and inserted
into pB, a plasmid encoding a truncated gB molecule under control of
the SP6 promoter (34). DNA sequence encoding this cysteine
mutation was transferred to a plasmid encoding the full-length gB
molecule under the control of the SP6 promoter. To transfer this
substitution to a full-length gB molecule driven by its natural
promoter (encoded by plasmid pKBXX) (8), the fragment
containing the serine-for-cysteine substitution was excised as a
3,084-bp BamHI-NotI fragment and cloned into
pKBXX digested with the same endonucleases, replacing wild-type
sequence with sequences encoding the cysteine substitution and
resulting in pKBXX(C633S). The additional substitution of nucleotide
sequences encoding a cysteine residue at position 596 for sequences
encoding a serine residue was generated by the PCR overlap extension
technique (28). pKBXX(C633S) served as template for the
creation of pKBXX(C596S/C633S), using primers 1 (5'-GCGGCTGTAGCTAGCCCC-3'), 2 (5'-GCCTCGGTCACCGTGGGC-3'), 3 (5'-CCCGGGGCTAGTTACAGC-3'), and 4 (5'-GCGCATGACCATGTCGG-3'). Amplification with primers 1 and 2 yielded a 200-bp fragment, and amplification with primers 3 and 4 yielded an 800-bp fragment. Amplification of the two PCR products with
primers 1 and 4, the external primers, yielded a 1,000-bp fragment
which was cloned into pKBXX(C633S) in order to obtain
pKBXX(C596S/C633S).
Construction of epitope-tagged mutant gB molecules.
The
nonapeptide epitope of influenza virus hemagglutinin (HA)
(49) was inserted as previously described (34) at
a unique NotI site between codons 41 and 42 of the gB
sequence (pKBXX), resulting in pKBXXHA. The HA epitope was transferred
to pKBXX(C633S) and pKBXX(C596S/C633S) to create pKBXXHA(C633S) and
pKBXXHA(C596S/C633S), respectively.
Construction and isolation of KgB(C633S) and KgB(C596S/C633S)
mutant viruses.
Mutant HSV-1 viruses were constructed by standard
methods for efficient marker transfer (16) by using
LipofectAmine reagent (Gibco-BRL) for cotransfection. KgB(C633S) and
KgB(C596S/C633S) mutant viruses were constructed by cotransfection of
plasmid pKBXX(C633S) or pKBXX(C596S/C633S) with K
4BX viral DNA on
the complementing A1 cell line. The mutant viruses were selected for
growth on D6 cells and screened by Southern blot hybridization using a
gB probe (Fig. 1) and plaque purified three times.
Immunoprecipitation analysis.
Virions released from cells
and infected cell lysates were prepared as follows. Confluent
60-mm-diameter dishes of Vero cells at 37°C were methionine-cysteine
starved for 4 h. Monolayers were infected with viruses at a
multiplicity of infection (MOI) of 10 and incubated for 48 h in
the presence of 100 µCi of [35S]methionine-cysteine
(NEN-Dupont, Boston, Mass.). Media containing radiolabeled virions were
cleared from cell debris by low-speed centrifugation, and the
supernatants were brought to a concentration of 1× lysis buffer, using
a 10× lysis buffer stock solution (200 mM Tris-HCl [pH 8.0], 1.5 M
NaCl, 10% Triton X-100, 10 mM
N
-p-tosyl-L-lysine chloromethyl ketone
[TLCK]). Detergent-denatured virions were sonicated and cleared by
centrifugation, and the supernatants were subjected to
immunoprecipitation. Infected cell monolayers were scraped in
Tris-buffered saline (TBS), the cell pellet was lysed in 1× lysis
buffer, sonicated, and cleared by centrifugation, and the supernatants
were subjected to immunoprecipitation. Immunoprecipitation was carried
out at 4°C using gB-specific monoclonal antibodies (MAbs) (gB-1 pool
or epitope-specific gB antibodies [36]), a gB MAb
which recognizes only dimeric gB (DL16; kindly provided by Gary H. Cohen and Roselyn J. Eisenberg, Philadelphia, Pa.), or the HA
epitope-specific antibody (12ca5J; Babco, Berkeley, Calif.). The
immunocomplexes were incubated with protein A-Sepharose (Sigma) for
1 h, centrifuged, washed with lysis buffer, and resuspended in
Laemmli buffer (33) before separation by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Following
electrophoresis, gels were fixed, treated with En3Hance
solution (NEN-Dupont), vacuum dried, and exposed to X-Omat-XAR film
(Kodak, Rochester, N.Y.). Films were developed and quantitated by using
the 1-D Scan and Report program (Biomed Instruments).
Analysis of released virions.
For detection of virions
released from infected cells, supernatants harvested 24 h
postinfection (p.i.) were cleared of debris by brief centrifugation at
3,000 rpm for 2 min and centrifuged at 20,000 × g for
45 min to pellet the virus. The virus pellets were resuspended in 0.5 ml of complete medium and applied to 30 to 65% sucrose gradients in
0.5× TBS, which were centrifuged at 23,000 × g in an
SWTI-41 rotor (Beckman) for at least 3 h. The virion band, visible
as a white cloudy ribbon, was extracted and subjected to
immunoprecipitation under native conditions (without detergent) with
gC-1 (37a)- or gB-1-specific MAbs in order to capture
released mature virions containing that envelope glycoprotein. Protein
A complexes were washed with complete medium in order to maintain the
integrity of the virus structure, and viral DNA extracted from the
antibody-captured virus was digested with BamHI and Southern
blotted as described above, or the captured virus was resuspended in
Laemmli buffer before separation by SDS-PAGE and Western blotting with
a VP5 polyclonal antibody (kindly provided by Gary H. Cohen and Roselyn
J. Eisenberg). An anti-rabbit antibody conjugated with horseradish
peroxidase (Sigma, St. Louis, Mo.) was used in conjunction with the ECL
(enhanced chemiluminescence) system (Amersham, Arlington Heights, Ill.)
for detection of bound VP5-specific antibody.
Immunofluorescence.
At 8 h p.i. or 24 h
posttransfection, Vero cell monolayers were fixed in ice-cold methanol
or left untreated prior to incubation at 34°C with the gB-1 MAb pool
(36) or a polyclonal antibody specific for the
carboxy-terminal domain of the gB molecule (kindly provided by Thomas
C. Holland, Wayne State University, Detroit, Mich.). Monolayers were
washed and incubated with a cy3-conjugated anti-mouse or anti-rabbit
antibody (Jackson Laboratory, West Grove, Pa.). The monolayers were
fixed with ice-cold methanol before photography with a Nikon model
211910 TMS microscope.
Oligomerization of mutant gB molecules with a truncated gB
molecule.
Monolayers of Vero cells were transfected with plasmid
pK
5C and/or plasmid pKBXXHA, pKBXXHA(C633S), or
pKBXXHA(C596S/C633S), using LipofectAmine reagent. Twenty-four hours
posttransfection, monolayers were infected with K
4BX virus at an MOI
of 10 in the presence of [35S]methionine-cysteine. Eight
hours p.i., cells were harvested in lysis buffer A (150 mM NaCl, 50 mM
Tris-HCl [pH 6.8], 1% Nonidet P-40, 1 mM TLCK) and subjected to
immunoprecipitation with a gB carboxy-terminal antibody or an influenza
HA MAb as described above. Samples were then separated by SDS-PAGE and
exposed to X-Ray film.
Endo H treatment of mutant gB molecules.
Confluent
monolayers of Vero cells were infected with KOS, KgB(C633S), or
KgB(C596S/C633S) virus at an MOI of 10. Six hours p.i., cells were
pulsed for 10 min with [35S]methionine-cysteine and
harvested in lysis buffer A (150 mM NaCl, 50 mM Tris-HCl [pH 6.8],
1% Nonidet P-40, 1 mM TLCK) or chased for indicated times before
harvesting. Lysates were sonicated, centrifuged, and subjected to
immunoprecipitation as previously described. Protein A-Sepharose
complexes were further washed with phosphate-buffered saline and
resuspended in 20 µl of endoglycosidase H (endo H) buffer (0.1 M
sodium citrate [pH 5.5], 0.1% SDS) in the presence or absence of 1 mU of endo H (Boehringer Mannheim, Indianapolis, Ind.). Following
overnight incubation at 37°C, samples were processed for separation
by SDS-PAGE as described above.
Inhibition of glucosidases I and II by CST.
Vero cells were
infected at an MOI of 10 with KOS, KgB(C633S), or KgB(C596S/C633S)
virus. Five hours p.i., medium was supplemented with 5 mM
castanospermine (CST; Sigma) and infected cells were further incubated
at 37°C for 45 min. Monolayers were pulsed and chased in the presence
of CST, harvested, and immunoprecipitated as described above.
Coimmunoprecipitation of gB molecules with calnexin,
calreticulin, and Grp78, using anticalnexin, anticalreticulin, and
anti-Grp78 antibodies.
Vero cells were infected with KOS,
KgB(C633S), or KgB(C596S/C633S) virus at an MOI of 10. Six hours p.i.,
cells were pulsed and chased for indicated times, harvested in lysis
buffer A, immunoprecipitated with the gB-1 MAb pool or anticalnexin,
anticalreticulin, or anti-Grp78 antibodies (StressGen, Victoria,
British Columbia, Canada), and separated by SDS-PAGE as described
above. Presence of gB molecules within anticalnexin, anti-Grp78, or
anticalreticulin coimmunoprecipitates was confirmed by Western blotting
using the polyclonal antibody against the carboxy-terminal domain of
gB. A second antibody against rabbit immunoglobulin G molecules labeled
with alkaline phosphatase was used to detect the presence of the
primary antibody against gB and revealed with nitroblue
tetrazolium-5-bromo-4-chloro-3-indolylphosphate substrates (Promega,
Madison, Wis.).
 |
RESULTS |
Construction of gB mutant viruses containing altered cysteine
residues.
Two mutant viruses were produced by marker rescue for
these studies. KgB(C633S) contained a single mutation in which a serine was substituted for cysteine at position 633, and KgB(C596S/C633S) contained a double mutation in which serine residues were substituted for cysteine at both amino acids 596 and 633. The substitution of
serine for cysteine at position 633 (Cys-633) resulted in the loss of
an ApaLI site, and the substitution at position 596 (Cys-596) resulted in the creation of a novel RmaI site. To
confirm these mutant virus genotypes, KgB(C633S) and KgB(C596S/C633S)
viral DNA samples were digested with NcoI and
ApaLI (Fig. 1A) or with NcoI and RmaI (Fig. 1B) and analyzed by Southern
blotting using a 32P-labeled gB probe consisting of an
NcoI fragment overlapping both mutation sites. The gB probe
hybridized to two fragments, 639 and 666 bp (indistinguishable on this
gel [Fig. 1A, lane 1]), from wild-type KOS viral DNA digested with
NcoI and ApaLI, while only a 1,305-bp fragment
was detected with the gB probe from either similarly digested mutant
viral DNA (Fig. 1A, lanes 2 and 3), confirming the serine substitution
at Cys-633. The labeled gB probe hybridized to a 1,259-bp fragment of
KOS and KgB(C633S) DNA digested with NcoI and
RmaI (Fig. 1B, lanes 1 and 2, respectively) but hybridized
to two fragments of 535 and 724 bp when KgB(C596S/C633S) DNA was
digested with these same endonucleases (Fig. 1B, lane 3), confirming
that the double mutant had a serine substitution at the second
location.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Southern blot analysis of the mutant KgB(C633S) and
KgB(C596S/C633S) viruses. An NcoI-digested 1,305-bp fragment
from gB was 32P labeled and used to Southern blot viral DNA
from KOS (lanes 1), KgB(C633S) (lanes 2), and KgB(C596S/C633S) (lanes
3). These viral DNA samples were digested with NcoI and
ApaLI (A) or RmaI (B). (A) The
[32P]gB probe hybridized with two fragments of 639 and
666 bp in KOS-digested DNA (lane 1, two indistinguishable bands on this
gel) and hybridized with one fragment of 1,305 bp in KgB(C633S)- and
KgB(C596S/C633S)-digested DNA, indicating the loss of an
ApaLI restriction site marking the gB mutation at amino acid
633. (B) The same [32P]gB probe hybridized to a fragment
of 1,259 bp in KOS-digested DNA (lane 1) as well as KgB(C633S)-digested
DNA (lanes 2) and hybridized to two fragments of 724 and 535 bp in
KgB(C596S/C633S)-digested DNA (lane 3), marking the insertion of an
RmaI restriction site and the gB mutation at amino acid 596. Positions of migration of the DNA standard are marked in kilobases on
each panel.
|
|
The single- and double-cysteine mutations resulted in the
production of noninfectious viruses lacking gB.
The gB mutant
viruses were unable to support infectious virus production on a
noncomplementing Vero cell line, indicating that the cysteine-to-serine
mutations were lethal; therefore, the gB mutant viruses were propagated
on gB-complementing Vero (D6) cells. The inability of both mutant
viruses to form plaques on normal Vero cells indicated that the
formation of disulfide bridges involving these two cysteine residues
was essential for functional gB and infectious virus production. This
inability could have resulted from enveloped particles either devoid of gB or containing nonfunctional gB. To distinguish between these possibilities, we determined whether extracellular virus contained the
mutant forms of gB and whether gB was present in an oligomeric form.
Vero cells infected with either cysteine mutant, a gB null mutant
(K

4BX grown on C1 cells), or wild-type KOS virus were radiolabeled
with [
35S]methionine-cysteine for 24 h. Purified
extracellular viruses
were extracted with nonionic detergent, and gB
was immunoprecipitated
from these extracts by using a pool of
gB-specific MAbs (Fig.
2A, lanes 1, 3, 5, and 7) and a MAb, DL16 (Fig.
2A, lanes 2, 4,
6, and 8), reactive with a
gB epitope present only in the oligomeric
form of gB. As shown in Fig.
2A, KOS virions contained gB in a
mature oligomeric form in the virus
envelope (lanes 1 and 2),
since gB was immunoprecipitated equally by
both MAbs. As expected,
no gB polypeptide was immunoprecipitated from
gB deletion mutant
virus K

4BX (lanes 3 and 4). Similarly, the
cysteine mutants [KgB(C633S)
and KgB(C596S/C633S)] failed to
incorporate the mutant gB molecules
into virion envelopes (lanes 5 or 6 and 7 or 8, respectively),
which accounts for their lack of infectivity
on noncomplementing
Vero cells.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 2.
Release of virions deficient in gB molecules from cells
infected with gB mutant viruses. Vero cells were infected with KOS,
KgB(C633S), KgB(C596S/C633S), or K 4BX virus, and C1 cells were
infected with K 4BX virus, in the presence (A and D) or absence (B
and C) of [35S]methionine-cysteine. Forty hours p.i.,
supernatants containing virions (A) and infected cells (D) were
harvested, solubilized, and subjected to immunoprecipitation with gB-1
MAb pool (B; lanes 1, 3, 5, and 7) or dimeric antibody (D; lanes 2, 4, 6, and 8), and the protein A-Sepharose immunocomplexes were separated
by SDS-PAGE. Twenty-four hours p.i., supernatants were harvested and
immunoprecipitated with gB-1 (B) or gC-1 (C) MAb pools before
separation by SDS-PAGE and Western blotting with a VP5 polyclonal
antibody. The positions of gB and VP5 are indicated by arrows at the
left.
|
|
To verify that the gB mutations did not preclude virus release,
supernatants of infected cells were examined for the presence
of
virions. Since the gB mutant viruses were noninfectious,
immunobiochemical
methods were used to detect their presence. We
reasoned that immunoprecipitation
using glycoprotein-specific
antibodies in combination with protein
A-Sepharose beads would capture
the virus particles if the glycoprotein
targeted by the antibody was
present in the virus envelope. The
presence of mature virus in these
immune complexes was confirmed
by detection of both viral DNA and the
major capsid protein VP5.
As shown in Fig.
2B, immune complexes of
virus particles from
KOS-, KgB(C633S)-, and KgB(C596S/C633S)-infected
Vero cell supernatants
and from K

4BX-infected C1 cell supernatant
(C1 cells provide
ICP 18.5) demonstrated release of virions from the gB
mutants
[KgB(C633S) and KgB(C596S/C633S)] or gB-deleted (C1 cells
infected
with K

4BX) infected cells. As expected, no VP5 was detected
in
immunoprecipitated samples from Vero cells infected with K

4BX,
due to the absence of the ICP 18.5 gene product, essential for
virus
egress (
46). In agreement with Fig.
2A, Fig.
2C demonstrates
that released virions from cells infected with wild-type virus
contained gB, while released virions from infections with KgB(C633S)
and KgB(C596S/C633S) were deficient in gB, as evidenced by the
lack of
VP5 in purified released virions immunoprecipitated with
the gB-1 MAb
pool. As expected, no VP5 was detected in immunoprecipitated
samples
from K

4BX infections on Vero (ICP 18.5, gB deletions)
or C1 (gB
deletion, ICP 18.5 provided in
trans) cells (Fig.
2C)
due to
the absence of gB. Southern blot analysis for the presence
of viral DNA
in glycoprotein immunoprecipitated virions gave results
similar to
those described above for the presence of VP5 (data
not shown).
The finding that the cysteine mutant gB molecules were not detected in
mature virions could have resulted from the inability
either to form
oligomers or to undergo proper processing and/or
intracellular
transport. To distinguish among these possibilities,
we first
determined whether the mutant molecules were capable
of forming
oligomers during infection (Fig.
2D). Cells infected
with mutant or
wild-type virus were radiolabeled as described
above, and
detergent-soluble infected cell extracts were treated
with the pool of
gB MAbs and the oligomer-specific antibody DL16
to determine the amount
of gB present in an oligomeric form. The
results of the SDS-PAGE
analysis of the immune complexes shown
in Fig.
2D demonstrated that
wild-type and cysteine mutant viruses
[KgB(C633S) and
KgB(C596S/C633S)] produced gB (lanes 1, 5, and
7, respectively) in a
dimeric form (lanes 2, 6, and 8, respectively).
Immunoprecipitation of
mutant gB molecules from cells infected
with KgB(C633S) or
KgB(C596S/C633S) demonstrated that the quantity
of mutant gB
immunoprecipitated by MAb DL16 (lanes 6 and 8, respectively)
was
approximately 50% less abundant than the quantity of mutant
gB
immunoprecipitated with the gB-1 MAb pool (lanes 5 and 7, respectively),
as quantified by densitometric analysis. No gB was
detected following
immunoprecipitation from C1 cells infected with
K

4BX (lanes 3
and 4) with either MAb, demonstrating the specificity
of the antibodies
used. These data showed that the cysteine mutant
viruses [KgB(C633S)
and KgB(C596S/C633S)] encoded a gB molecule
capable of forming
homo-oligomers, albeit apparently less efficiently
than a wild-type
gB molecule. Alternatively, the reduced amount of
oligomeric gB
detected by antibody DL16 could be due to a change in the
structure
formed by the mutant oligomer-component epitopes, resulting
in
reduced quantities of immunoprecipitated product.
To distinguish between these possibilities, a coimmunoprecipitation
assay was performed to detect oligomeric complexes of
proteins that did
not involve antibody recognition of a dimer-specific
epitope. In these
experiments, Vero cells were cotransfected with
plasmids which
expressed an oligomerization-competent, truncated
form of gB and either
the full-length wild-type or cysteine mutant
gB molecule. Following
infection by a gB null mutant virus in
order to transactivate gB
expression from the plasmids, the formation
of hetero-oligomers between
the truncated oligomer partner and
normal-length wild-type or cysteine
mutant gB molecule could be
detected by antibodies reactive with the
full-length member of
the oligomer pair. If oligomerization occurred,
the immune complexes
would also contain the truncated second member of
the pair. Because
the partners were of different lengths, they could be
readily
distinguished by their different molecular ratios following
SDS-PAGE
analysis of the immunoprecipitates.
Vero cells were cotransfected with a plasmid that expressed an
N-terminal HA-tagged full-length wild-type (gBHA) or cysteine
mutant gB
molecule [gBHA(C633S) or gBHA(C596S/C633S)] and plasmid
pK

5C,
which expressed a truncated oligomerizing form of gB deleted
for
residues 43 to 596 (
26). The cotransfected cells were
subsequently
infected with K

4BX, and 6 h p.i., the cell
monolayers were radiolabeled
with
[
35S]methionine-cysteine for 3 h before
solubilization with a nonionic
detergent. As shown in Fig.
3, the truncated as well as full-length
wild-type and mutant gB molecules were detected by immunoprecipitation
using a polyclonal antiserum (Abc) that reacted with their carboxy
termini (lanes 3, 5, 7, and 9) while the full-length HA epitope-bearing
molecules were detected with an HA-reactive (AbHA) MAb (lanes
6, 8, and
10). No labeled protein was immunoprecipitated from
cells that were
mock transfected and infected with the null mutant
virus (lanes 1 and
2). We first confirmed that wild-type gB formed
oligomers with
truncated gB by demonstrating that both molecules
were present in the
immune complexes when the AbHA antibody was
used to immunoprecipitate
the HA-tagged gB molecule cotransfected
with the truncated gB molecule
(lane 12). The two proteins were
identified by analysis of
immunoprecipitates resulting from the
use of the Abc antibody (lane
11). We then tested the ability
of the HA-tagged single- and
double-cysteine mutant forms of gB
to oligomerize with the truncated gB
molecule. As seen in lanes
14 and 16, the mutant molecules formed
oligomers to an extent
similar to the wild-type gB molecule, confirming
the results using
the oligomer specific antibody (Fig.
2D).
Quantification by densitometry
of the truncated gB molecule
coimmunoprecipitated with the full-length
wild-type or cysteine-mutated
gB molecules demonstrated that the
cysteine-mutated gB molecules
oligomerized as efficiently as the
wild type with the truncated gB
peptide and suggested that because
less mutant homo-oligomers were
immunoprecipitated using antibody
DL16 (Fig.
2D), this
oligomer-dependent epitope was altered by
one or two cysteine
mutations. Together, the results of these
studies indicate that
oligomerization of gB did not require the
formation of a disulfide
bridge between Cys-596 and Cys-633 and
the failure to incorporate gB
into extracellular virus was not
due to a defect in oligomerization.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Ability of mutant gB molecules to form hetero-oligomers.
Vero cell monolayers were mock transfected (lanes 1 and 2) or
transfected individually with a plasmid encoding a truncated gB
molecule (pK 5C; lanes 3 and 4), HA-tagged gB molecule (gBHA; lanes 5 and 6), or recombinant HA-tagged gB molecules [gBHA(C633S) or
gBHA(C596S/C633S); lanes 7 and 8 or lanes 9 and 10, respectively].
Monolayers were also cotransfected with a plasmid encoding the
truncated gB molecule (pK 5C) and gBHA (lanes 11 and 12), gBHA(C633S)
(lanes 13 and 14), or gBHA(C596S/C633S)S (lanes 15 and 16). Twenty-four
hours posttransfection, cells were infected with a gB-deleted virus
(K 4BX) at an MOI of 10 in the presence of
[35S]methionine-cysteine. Seven hours p.i., cell
monolayers were harvested and immunoprecipitated with a polyclonal
antibody directed against the carboxy-terminal region of gB (Abc; lanes
1, 3, 5, 7, 9, 11, 13, and 15) or anti-HA antibody (AbHA; lanes 2, 4, 6, 8, 10, 12, 14, and 16). The protein A-Sepharose immunocomplexes were
separated by SDS-PAGE. The positions of the HA-tagged wild-type and
mutant gB molecules (all gBHA) as well as the truncated gB molecule are
marked at the right. Molecular size markers are indicated in
kilodaltons at the left of the figure.
|
|
The cysteine mutant forms of gB are not transported to the surface
membrane of infected cells.
Because the cysteine mutant gB
molecules were translated and formed oligomers but were absent in
mature virus particles, it appeared likely that a defect in processing
and/or trafficking of these mutant molecules accounted for their lack
of incorporation into virions. In addition, immunoprecipitates from
KOS-infected cells showed two forms of gB which are typically the major
gB precursor and final products whereas the cysteine mutant viruses appeared to produce only the precursor form, further suggesting that
the mutant molecules were incompletely processed (Fig. 2D).
To further examine the processing of the mutant gB molecules, we first
determined whether these molecules were transported
to the cell surface
of infected cells (Fig.
4). Vero cells
were
infected with KOS, KgB(C633S), or KgB(C596S/C633S) (lane 1, 2,
or
3, respectively) for 24 h, and the presence of gB on the infected
cell surface membrane was detected by indirect immunofluorescence
using
a gB-specific MAb pool. The results, shown in Fig.
4B, demonstrated
that only wild-type KOS virus-infected cells expressed gB on the
cell
surface, while all infections [KOS, KgB(C633S) and KgB(C596S/C633S)]
contained gB in the cytoplasm, as demonstrated by indirect
immunofluorescence
using methanol-permeabilized infected cells (Fig.
4A). These data
clearly showed that the cysteine mutations interfere
with normal
trafficking of gB to the cell surface.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 4.
Failure of the mutant gB molecules to be transported to
the cell surface of infected cells. Ten hours p.i., monolayers of Vero
cells infected with KOS (row 1), KgB(C633S) (row 2), or
KgB(C596S/C633S) (row 3) virus at an MOI of 10 were fixed in ice-cold
methanol (A) or left untreated (B). Monolayers were then incubated with
the gB-1 MAb pool followed by incubation with cy3-conjugated anti-mouse
antibody. Monolayers were visualized with a model 211910 Nikon
microscope and photographed.
|
|
The cysteine mutant gB molecules are glycosylated in the ER but
fail to be transported to the Golgi complex.
Processing of the
HSV-1 glycoproteins during infection occurs through successive stages
that involve addition of the mannose core sugars, trimming of the
glucose residues by glucosidases I and II, and trimming of the mannose
residues within the ER. These processed forms become resistant to endo
H as the maturing glycoproteins migrate through the Golgi complex.
Because the cysteine mutant gB molecules were translated and formed
oligomers but were not transported to the cell surface or incorporated
into virus envelopes, it appeared that the cysteine mutations prevented
complete processing of the mutant gB molecules.
We first examined whether the mutant gB forms were transported to the
Golgi complex based on their resistance to endo H treatment.
Vero cells
infected with KOS or the cysteine mutant viruses were
pulse-labeled
with [
35S]methionine-cysteine for 10 min and chased with
isotope-free
medium for 1, 2, or 3 h. Infected cell lysates were
immunoprecipitated
with a gB-specific MAb pool, and a sample of the
immune complexes
was treated with endo H. Both treated and untreated
samples were
analyzed by SDS-PAGE and autoradiography to determine the
relative
sensitivities of the gB mutants to endo H compared with that
of
wild-type gB. As shown in Fig.
5A,
KOS-derived gB was readily
digested by endo H (lanes 1 and 2) prior to
chase, indicating
that the mannose core sugars had not been trimmed and
the newly
labeled gB still localized to the ER. However, after a 1-h
chase,
a portion of wild-type gB became resistant to endo H and
migrated
at a higher molecular ratio than the endo H-sensitive gB
product,
indicating that the mannose core sugars had been replaced with
more complex carbohydrates (lanes 3 and 4) and that wild-type
gB had
begun its migration to the Golgi complex. The amount of
endo
H-resistant gB increased at the 2- and 3-h chase periods
(lanes 6 and
8). In contrast to these results, experiments involving
the cysteine
mutants showed that gB remained completely sensitive
to endo H
digestion even after an extended chase period of 3 h
[lanes 7 and
8 in Fig.
5B and C for KgB(C633S) and KgB(C596S/C633S),
respectively],
demonstrating that the cysteine mutant gB molecules
remained associated
with the ER. These observations clearly showed
that the mutant forms of
gB were not transported to the Golgi
complex and remained associated
with the ER even in experiments
where the chase period was extended to
10 h (data not shown).
Similar experiments were performed with the
dimer-specific antibody
(DL16) and similar data were obtained (data not
shown), suggesting
that wild-type gB and cysteine mutants formed
oligomers in the
ER soon after synthesis (10-min pulse).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 5.
Endo H sensitivity of mutant gB molecules. Vero cell
monolayers were infected with KOS (A), KgB(C633S) (B), or
KgB(C596S/C633S) (C) virus at an MOI of 10. Six hours p.i., monolayers
were pulse-labeled for 10 min in the presence of
[35S]methionine-cysteine and lysed immediately (Pulse;
lanes 1 and 2) or further incubated in complete media and harvested
after 1, 2, or 3 h of chase (lanes 3 and 4, 5 and 6, or 7 and 8, respectively). Samples were solubilized and subjected to
immunoprecipitation with the gB-1 MAb pool, captured with protein
A-Sepharose, incubated in absence ( ) or presence (+) of endo H, and
separated by SDS-PAGE. Molecular size markers are indicated in
kilodaltons at the left.
|
|
Since the mutant gB products were not transported from the ER to the
Golgi complex, we performed experiments to further define
the step in
processing where the mutant gB forms were retained.
Glucosidases I and
II are glucose-trimming enzymes located within
the ER whose function is
inhibited by CST (
18). To determine
whether the mutant gB
molecules were sensitive to glucosidase
I and II trimming activity, KOS
and cysteine mutant infections
were pulse-radiolabeled and chased with
cold medium in the presence
and absence of CST. Infected cell extracts
were immunoprecipitated
with anti-gB antibodies, and the immune
complexes were analyzed
by SDS-PAGE and autoradiography (Fig.
6). KOS gB appeared as a
doublet,
indicative of a precursor product relationship between
gB in the ER and
gB which had migrated to the Golgi complex for
terminal sugar addition
(Fig.
6, lane 1). Immune complexes from
wild-type virus infections
treated with CST contained a product
that migrated at a higher
molecular mobility (lane 2) than the
untreated gB samples (lower band
of doublet seen in lane 1), demonstrating
that CST inhibited the
trimming of wild-type gB. Similar results
were obtained with the
cysteine mutant virus infections [lanes
3 to 6, KgB(C633S) and
KgB(C596S/C633S)]. These results showed
that the mutant forms of gB
were modified by glucosidase I and
II similarly to wild-type gB.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
Processing of mutant gB by glucosidases I and II. Vero
cell monolayers were infected with KOS (A), KgB(C633S) (B), or
KgB(C596S/C633S) (C) virus at an MOI of 10. Five hours p.i., cells were
preincubated in the absence ( ; lanes 1, 3, and 5) or presence (+;
lanes 2, 4, and 6) of CST for 1 h. Infected cells were
pulse-labeled for 10 min in the presence of
[35S]methionine-cysteine and chased for 2 h in
absence or presence of CST. Monolayers were harvested, solubilized, and
subjected to immunoprecipitation with a gB-1 MAb pool, and protein
A-Sepharose immunocomplexes were separated by SDS-PAGE.
|
|
The cysteine mutations prevented release by the molecular
chaperones calnexin, Grp78, and calreticulin.
The experiments
above demonstrated that the cysteine mutant gB molecules were retained
in the ER (Fig. 6) at a step following trimming by glucosidases I and
II. Calnexin, Grp78, Grp94, and calreticulin, which are ER-resident
chaperone molecules, interact with glycoproteins and mediate protein
folding and oligomerization; misfolded proteins are retained by these
chaperones, preventing further processing (22a, 22b).
Calnexin has been demonstrated to bind to maturing HSV-1 gB
(51), while calnexin, Grp78, Grp94, and calreticulin have
been demonstrated to associate with maturing human cytomegalovirus gB
(52). Together, these proteins may form a quality control
complex which ensures proper protein folding and oligomerization
(18a, 39a, 45a). To examine the possibility that improperly
folded glycoproteins are retained in the ER by calnexin, Grp78, and/or
calreticulin, we performed experiments in which antichaperone
antibodies were used to determine whether the mutant gB products could
be coimmunoprecipitated (Fig. 7). Vero
cells were infected with KOS, KgB(C633S), or KgB(C596S/C633S). The
infected cells were pulse-radiolabeled for 10 min and chased with
complete medium for 1, 3, or 7 h before detergent extraction and
treatment with an anticalnexin, anti-Grp78, or anticalreticulin antibody. As shown in Fig. 7, immunoprecipitation of the pulse-labeled samples (lanes P) with each chaperone antibody resulted in the presence
of gB in the immune complexes, demonstrating that the chaperones
initially associated with gB. The identity of gB was confirmed by
Western blot analysis using an anti-gB antibody reactive with the
cytoplasmic domain (data not shown). However, pulse-labeled wild-type
gB became uncoupled from each chaperone by 3 h of chase, showing
that it was released by the chaperone molecule to continue on its
pathway to the Golgi complex. Similar to wild-type gB and in agreement
with an earlier report (51), gC and gD were also coimmunoprecipitated by the anticalnexin antibody and were uncoupled following a 3-h chase period, indicating that calnexin is involved in
chaperoning multiple HSV-1 glycoproteins (data not shown). The results
of similar immunoprecipitation experiments using KgB(C633S)- and
KgB(C596S/C633S)-infected cells showed that in contrast to wild-type
gB, calnexin, Grp78, and calreticulin were continuously associated with the cysteine mutant gB molecules even after a 7-h chase
period. These data suggested that the cysteine mutations altered the
conformation of gB in a manner to prevent dissociation from ER
chaperones.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 7.
Retention of mutant gB molecules in the ER by calnexin,
Grp78, and calreticulin. Vero cell monolayers were infected with KOS,
KgB(C633S), or KgB(C596S/C633S) virus at an MOI of 10. Six hours p.i.,
monolayers were pulse-labeled for 10 min in the presence of
[35S]methionine-cysteine and lysed immediately (Pulse;
lanes P) or further incubated in complete medium and harvested after 1, 3, or 7 h (Chase). Samples were solubilized and subjected to
immunoprecipitation with anticalnexin (A), anti-Grp78 (B), or
anticalreticulin (C) polyclonal antibodies. Protein A-Sepharose
immunocomplexes were separated by SDS-PAGE in order to visualize gB
molecules which coprecipitated with the various chaperones.
|
|
The cysteine mutations alter conformationally dependent antigenic
sites.
Since gB mutated in Cys-633 alone or in combination with
Cys-596 remained bound to molecular chaperones of the ER, it was likely
that these mutations affected gB folding at least in the region where
these two cysteines form a disulfide bridge, and possibly in other
regions of gB as well. These conformational changes might be reflected
in the alteration of nonlinear epitopes detected by MAbs which
recognize distinct antigenic sites on gB. Previously, we reported that
gB contains at least four antigenic sites, three of which were
nonlinear conformationally dependent determinants (36).
These determinants were designated site I (residues 381 to 441), site
II (residues 595 to 737), and site III (residues 283 to 380) recognized
by the cognate MAbs B3, B8, and B4, respectively. A polyclonal antibody
directed against the carboxy-terminal region of gB (Fig.
8A) could be used to immunoprecipitate wild-type or gB mutant molecules present in each sample as a control for the total amount of gB detectable by immunoprecipitation. The
site-specific MAbs (Fig. 8B to D) were exploited to discern possible
regional conformational changes within the cysteine mutant forms of gB.
If any of these antibodies failed to bind or showed reduced binding
compared with the total quantity of gB present in each sample, the
retention of the mutant gB molecules in the ER could be associated with
a conformational change colocalizing with the affected epitope
structure.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 8.
Immunoprecipitation of mutant gB molecules with
epitope-specific gB antibodies. Vero cell monolayers were infected with
KOS (lane 1), KgB(C633S) (lane 2), and KgB(C596S/C633S) (lane 3)
viruses at an MOI of 10 in the presence of
[35S]methionine-cysteine. Forty hours p.i., infected
cells were harvested, solubilized, and subjected to immunoprecipitation
with a polyclonal antibody directed against the carboxy terminus of gB
(A) or MAb B4 (B), B8 (C), or B3 (D). Protein A-Sepharose complexes
were separated by SDS-PAGE.
|
|
Vero cells infected in the presence of
[
35S]methionine-cysteine with either KOS, KgB(C633S), or
KgB(C596S/C633S) (lane 1, 2,
or 3, respectively) were extracted with
detergent and immunoprecipitated
with the three representative MAbs.
The amount of gB present in
these samples was compared to the amount of
gB immunoprecipitated
with the polyclonal antibody for each virus. As
shown in Fig.
8B, MAb B4 immunoprecipitated similar amounts of gB from
wild-type-infected
(lane 1) and the two gB mutant virus-infected (lanes
2 and 3)
cell extracts compared with the quantity of gB molecule
immunoprecipitated
by the polyclonal antibody. These results indicated
that the site
III epitope recognized by MAb B4 was undisturbed by the
cysteine
mutations. In contrast, MAb B8 (which recognizes site II
containing
the cysteine mutations [Fig.
8C]) immunoprecipitated 30 and 45%
of the amount of the mutated gB molecules from KgB(C633S) and
KgB(C596S/C633S) viruses, respectively, compared to the amount
of gB
protein immunoprecipitated by the polyclonal antibody, while
wild-type
gB was immunoprecipitated to the same extent. These
data demonstrated
that mutation of Cys-633 or both Cys-596 and
Cys-633 altered the
conformation of the MAb B8 epitope. Immunoprecipitation
with MAb B3
(which recognizes site I, a distal site from the cysteine
mutations
[Fig.
8D]) also showed a reduction in the amount of
gB
immunoprecipitated from the gB mutant viruses. The amount of
gB
immunoprecipitated from KgB(C633S) and KgB(C596S/C633S) with
MAb B3,
compared to the amount of gB immunoprecipitated with the
polyclonal
antibody, represented 62 and 89%, respectively, of
the product
immunoprecipitated by the polyclonal antibody, indicating
that a distal
epitope from the cysteine mutations was also altered
in the mutant gB
molecules. Together, these data demonstrated
that epitopes I and II
were altered by interrupting the Cys-633
to Cys-596 disulfide bridge,
confirming that the cysteine mutations
caused gB to be misfolded in
several distinct molecular regions.
These disruptions in normal folding
of gB most likely accounted
for chaperone-mediated retention of these
molecules in the ER.
Hetero-oligomers between mutant and wild-type gB molecules are not
properly transported to the cell surface of infected cells.
We
demonstrated above that the cysteine mutant forms of gB were capable of
forming homo-oligomers (Fig. 2) and hetero-oligomers with truncated gB
molecule (Fig. 3). However, in Fig. 4 we showed that the mutated gB
oligomers were not transported to the cell surface of infected cells
due to a conformational misfolding of the mutated proteins (Fig. 8),
blocking their release from the ER (Fig. 5) by chaperone molecules
(Fig. 7). To determine whether hetero-oligomerization of these mutant
gB molecules with wild-type gB might restore their conformational
structure, allowing escape from chaperone retention, we tested for the
presence of mutated gB molecules at the cell surface of infected cells
following hetero-oligomerization with wild-type gB. Cells were
transfected with expression plasmids for HA-tagged KOS or the cysteine
mutant gB molecules, followed by infection with wild-type virus to
provide a source of conformationally intact gB. The presence of mutant
and wild-type gB forms at the cell surface was examined on
nonpermeabilized infected cells by indirect immunofluorescence using a
polyclonal anti-HA antibody. As shown in Fig.
9A, wild-type and cysteine mutant
HA-tagged gB molecules were readily detected in the cytoplasm of
methanol-fixed cells by the HA epitope-reactive antibody, demonstrating
that the transfections of plasmid encoding HA-tagged wild-type (row 1)
and mutated (rows 2 and 3) gB resulted in gB production. Moreover, gB
was detected at the cell surface in all infections since a pool of
gB-specific MAbs detected gB (from wild-type virus production and
potentially plasmid expression) on nonpermeabilized cells (Fig. 9B).
However, in contrast to gBHA (Fig. 9C, row 1), both mutant gB molecules
failed to reach the cell surface (Fig. 9C, rows 2 and 3), as
demonstrated by the absence of HA epitope detection at the cell surface
of nonpermeabilized cells. Therefore, despite the ability of the
cysteine mutants to oligomerize with wild-type gB, the hetero-oligomers
were not transported to the cell surface. Although not tested, these
results suggested that the hetero-oligomers were not incorporated into
virions and indeed the presence of these nonfunctional oligomeric forms
can inhibit efficient complementation by the wild-type molecule
(9, 16, 26).

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 9.
Failure of the mutant gB molecules to be transported to
the cell surface in the presence of wild-type gB as detected by
immunofluorescence analysis. Vero cell monolayers were individually
transfected with HA-tagged gB (gBHA; row 1), gB(C633S) [gBHA(C633S);
row 2], or gB(C596S/C633S) [gBHA(C596S/C633S); row 3]. Twenty-four
hours posttransfection, monolayers were infected with KOS at an MOI of
5. Eight hours p.i., cells were fixed in ice-cold methanol (A) or left
untreated (B and C) and incubated with anti-HA (A and C) or gB-1 MAb
pool (B) antibodies followed by incubation with a cy3-conjugated
anti-mouse antibody. Cells were visualized with a model 211910 Nikon
microscope and photographed.
|
|
 |
DISCUSSION |
gB is a multifunctional essential virus envelope component which
has been extensively studied using genetic and biochemical approaches.
Experiments described in this report were designed to evaluate the role
of two highly conserved cysteine residues of gB in oligomer formation,
processing in the ER, transport to the cell surface, and incorporation
into mature infectious virus particles. We created a single mutant in
which a cysteine residue (Cys-633) located within the gB
oligomerization domain was replaced by serine and studied it during
infection to determine whether oligomers would form during the virus
lytic cycle and support active virus production. The double mutant was
created to prevent the possible formation of aberrant disulfide bonds
by the unpaired cysteine partner at position 596 (Cys-596). A single
mutant with a substitution at Cys-596 was not generated since this
mutation was located outside the oligomerization domain. The results of this study support the conclusion that cysteines 633 and 596 are not
required for oligomerization but are critical to the structural integrity of gB and essential for the development of a
three-dimensional structure that allows this molecule to be normally
processed and incorporated into mature virions.
gB was first determined to oligomerize shortly after synthesis as
detergent-stable, heat-dissociable dimeric forms on PAGE (11). Homo-dimers have also been detected by sedimentation
analysis of gB from purified virus, suggesting that the active form of gB is an oligomer (8). The tight association of wild-type gB monomer subunits can form unique epitopes which are recognized by MAbs
that bind only to the oligomer. These antibodies have proven valuable
in detecting the timing of oligomer formation following gB translation.
In this study, oligomers were detected very early (within 10 min)
following gB synthesis and likely occur concurrent with translation.
This conclusion is consistent with the demonstration that the
glycosylation inhibitor tunicamycin does not block oligomerization
(26). Oligomerization of gB is also supported by evidence
that hetero-oligomers composed of defective and wild-type gB monomer
subunits were not functionally active and moreover interfere with the
active form by reducing the formation of functional oligomers (wild
type-wild type), whereas a mutant form which could not form oligomers
did not interfere with the production of active oligomers (8,
16). This form of complementation interference was also observed
with the cysteine gB mutant molecules constructed in this study since
we demonstrated that hetero-oligomers composed of wild-type and mutant
gB molecules were not processed and transported to the cell surface.
These observations indicated that the gB mutant monomer subunits were
not functionally corrected by association with a wild-type monomer
subunit.
Using a coimmunoprecipitation assay, two oligomer-forming regions were
identified within the external domain of gB (26): an
upstream site between residues 93 and 282 and a downstream site located
between residues 595 and 711. The upstream site was shown to provide
only a weak interaction between gB monomers, while the downstream site
caused a stronger association between monomers (16, 26) and
was the only site identified by a functional inhibitory antibody
approach where antibodies directed against this site blocked
oligomerization (42). We recently reported studies to
further characterize the downstream site by using an in vitro
coimmunoprecipitation assay (34). This site was shown to be
limited to 28 residues (amino acids 626 through 653) and could form
oligomers when relocated to the carboxy terminus of gB, demonstrating
that the oligomer-forming domain is a movable element and can
self-associate in a manner independent of its local protein
environment. An interesting feature of this domain was the presence of
a cysteine residue at position 633 that was recently reported to form a
disulfide bridge with cysteine 596 located outside the oligomer domain
in HSV-2 gB (39). Because the type 1 and type 2 molecules
are highly homologous and their cysteines are located in precisely the
same positions, it is reasonable to propose that the type 1 molecule
forms similar if not identical disulfide bridges (39).
Conversion of cysteine 633 to serine did not block dimer formation;
however, oligomerization was approximately half as efficient
(34). We also found that oligomerization did not depend on
the predicted disulfide bridge between Cys-596 and Cys-633 but that
oligomerization was not sufficient to allow for correct gB processing
and incorporation into virus particles. These data suggested that
Cys-633 and Cys-596 were essential for proper gB folding, processing,
intracellular trafficking, and virion incorporation.
Calnexin and calreticulin are two homologous, lectin-like chaperone
molecules located in the ER that bind to partially trimmed, monoglucosylated forms of the N-linked core glycans present on maturing
proteins (3, 22, 37a). They promote proper folding, prevent
premature oligomerization, inhibit degradation, and function as quality
control mediators for a variety of glycoproteins (22a, 22b, 23,
30, 48). Grp78 and Grp94 are soluble proteins also located in the
ER which assist protein folding and prevent the exit of molecules that
fail to attain the proper conformation (22a, 22b). In our
study, we demonstrated that wild-type gB transiently associates with
calnexin, Grp78, and calreticulin, in contrast to the cysteine mutant
gB forms, which remained associated with calnexin, Grp78, and
calreticulin for at least 7 h, accounting for their arrested
maturation in the ER. These data are in agreement with previous reports
demonstrating that HSV-1 glycoproteins gB, gC, and gD associate with
calnexin following partial trimming of N-linked oligosaccharides
(51) and that mutant forms of gB from HSV-1 and human
cytomegalovirus formed complexes with Grp78 and Grp94, causing their
retention in the ER (38, 52). Taken together, these data
suggested that the ER-resident chaperones recognized misfolded proteins
not based on a sequence-specific mutation but rather based on the
entire protein conformation. The fact that the cysteine gB mutants were
retained simultaneously instead of sequentially in the ER by calnexin,
Grp78, and calreticulin suggested that in agreement with findings of
others (18a, 39b, 45a), the chaperone proteins may form a
complex as part of an extended network of molecules in the ER that
direct the processing of proteins.
Direct evidence for altered conformation of the cysteine mutant gB
forms was provided by their reduced recognition by MAbs that recognize
epitopes located within the affected domains. The predicted disulfide
bridge between cysteines 9 and 10 (Cys-596 and Cys-633, respectively)
was required to maintain the structure of these conformational
epitopes, and the impact of these mutations had a far-reaching impact
on the molecule since two antigenic sites were altered. The alterations
were nevertheless subtle since the antibodies could still recognize the
molecules but with substantially less avidity. These cysteine mutations
did not affect the temperature-dependent stability of these molecules
since they were not functional in processing at temperatures ranging
from 25 to 39°C (unpublished observation).
Despite the fact that the cysteine mutant forms of gB remained
associated with chaperone molecules in the ER, mature virus was
released from infected cells completely lacking gB but had the normal
complement of the other glycoproteins (gC and gD) as measured by
Western blot analysis of purified extracellular virus envelope
components. Since gB is essential to virus entry, the absence of gB in
the virus envelope accounted for the failure of these mutant viruses to
produce infectious particles. Browne et al. (5) recently
reported that an ER-restricted gH mutant of HSV-1 lacked gH in virus
particles and virus produced was noninfectious. Consistent with this
report, biochemical analysis of the cysteine mutant viruses revealed
the presence of the mutant gB proteins within the infected cells but
their absence in the envelope of mature extracellular virions. Both the
gH experimentation and the present study suggest that envelopment may
occur in a post-ER compartment such as the Golgi complex, Golgi-derived
vacuoles, or the plasma membrane. Alternatively, mutant gB forms are
never incorporated into budded particles at the nuclear membrane and the double-enveloped viruses released from the ER undergo membrane exchange at the Golgi complex, where maturing viruses acquire their
final envelope. Studies to define the trafficking patterns of these
cysteine gB mutant molecules and envelope contents of intracellular
mutant virus particles are under way and may help to better define the
pathway(s) leading to mature virus production.
 |
ACKNOWLEDGMENTS |
Sylvie Laquerre and Dina B. Anderson contributed equally to this
research.
We thank Darren P. Wolfe for discussion of the data and Thomas C. Holland for critical reading of the manuscript.
This work was supported by Public Health Service grant R01 CA66141-07
from the National Institutes of Health, by l'Association Française contre les Myopathies, and by GenVec Inc.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Genetics and Biochemistry, University of Pittsburgh School of
Medicine, E1240 Biomedical Science Tower, Pittsburgh, PA 15261. Phone:
(412) 648-8106. Fax: (412) 624-8997. E-mail:
joe{at}server1.mgen.pitt.edu.
Present address: Biotechnology Center, University of Ferrara,
Ferrara I-44100, Italy.
 |
REFERENCES |
| 1.
|
Albrecht, J.-C., and B. Fleckenstein.
1990.
Structural organization of the conserved block or Herpesvirus saimiri coding for DNA polymerase, glycoprotein B, and major DNA binding protein.
Virology
174:533-542[Medline].
|
| 2.
|
Anderson, K. S., and P. Cresswell.
1994.
A role for calnexin (IP90) in the assembly of class II MHC molecules.
EMBO J.
13:675-682[Medline].
|
| 3.
|
Bergeron, J. J. M.,
M. B. Brenner,
D. Y. Thomas, and D. B. Williams.
1994.
Calnexin: a membrane-bound chaperone in the endoplasmic reticulum.
Trends Biochem. Sci.
19:124-128[Medline].
|
| 4.
|
Bond, V. C.,
S. Person, and S. C. Warner.
1982.
The isolation and characterization of mutants of herpes simplex virus type 1 that induce cell fusion.
J. Gen. Virol.
61:245-254[Abstract/Free Full Text].
|
| 5.
|
Browne, H.,
S. Bell,
T. Minson, and D. W. Wilson.
1996.
An endoplasmic reticulum-retained herpes simplex virus glycoprotein H is absent from secreted virions: evidence for reenvelopment during egress.
J. Virol.
70:4311-4316[Abstract].
|
| 6.
|
Bzik, D. J.,
B. A. Fox,
N. A. DeLuca, and S. Person.
1984.
Nucleotide sequence specifying the glycoprotein gene, gB, of herpes simplex virus type 1.
Virology
133:301-314[Medline].
|
| 7.
|
Cai, W.,
B. Gu, and S. Person.
1988.
Role of glycoprotein B of herpes simplex virus type 1 in viral entry and cell fusion.
J. Virol.
62:2596-2604[Abstract/Free Full Text].
|
| 8.
|
Cai, W.,
S. Person,
C. DebRoy, and B. Gu.
1988.
Functional regions and structural features of the gB glycoprotein of herpes simplex virus type 1: an analysis of linker insertion mutants.
J. Mol. Biol.
201:575-588[Medline].
|
| 9.
|
Cai, W.,
S. Person,
S. C. Warner,
J. Zhou, and N. A. DeLuca.
1987.
Linker-insertion nonsense and restriction-site deletion mutations of the gB glycoprotein gene of herpes simplex virus type 1.
J. Virol.
61:714-721[Abstract/Free Full Text].
|
| 10.
|
Chapsal, J. M., and L. Pereira.
1988.
Characterization of epitopes on native and denatured forms of herpes simplex virus glycoprotein B.
Virology
164:427-434[Medline].
|
| 11.
|
Claesson-Welsh, L., and P. G. Spear.
1986.
Oligomerization of herpes simplex virus glycoprotein B.
J. Virol.
60:803-806[Abstract/Free Full Text].
|
| 12.
|
Claesson-Welsh, L., and P. G. Spear.
1987.
Amino-terminal sequence, synthesis, and membrane insertion of glycoprotein B of herpes simplex virus type 1.
J. Virol.
61:1-7[Abstract/Free Full Text].
|
| 13.
|
Darlington, R. W., and L. H. Moss.
1968.
Herpesvirus envelopment.
J. Virol.
2:48-55[Abstract/Free Full Text].
|
| 14.
|
David, V.,
F. Hochstenbach,
S. Rajagopalan, and M. Brenner.
1993.
Interaction with newly synthesized and retained proteins in the endoplasmic reticulum suggests a chaperone function for human integral membrane protein IP90 (calnexin).
J. Biol. Chem.
268:9585-9592[Abstract/Free Full Text].
|
| 15.
|
DeLuca, N.,
D. J. Bzik,
V. C. Bond,
S. Person, and W. Snipes.
1982.
Nucleotide sequences of herpes simplex type 1 (HSV-1) affecting virus entry, cell fusion, and production of glycoprotein gB (VP7).
Virology
122:411-423[Medline].
|
| 16.
|
Desai, P.,
F. L. Homa,
S. Person, and J. C. Glorioso.
1994.
A genetic selection method for the transfer of HSV-1 glycoprotein B mutations from plasmid to the viral genome: preliminary characterization of transdominance and entry kinetics of mutant viruses.
Virology
204:312-322[Medline].
|
| 17.
|
Desai, P. J.,
P. A. Schaffer, and A. C. Minson.
1988.
Excretion of non-infectious virus particles lacking glycoprotein H by a temperature-sensitive mutant of herpes simplex virus type 1: evidence that gH is essential for virion infectivity.
J. Gen. Virol.
69:1147-1156[Abstract/Free Full Text].
|
| 18.
|
Elbein, A. D.
1987.
Inhibitors of biosynthesis and processing of N-linked oligosaccharide chains.
Annu. Rev. Biochem.
56:497-534[Medline].
|
| 18a.
|
Ferreira, L.,
K. Norris,
T. Smith,
C. Hebert, and J. Sauk.
1996.
Hsp47 and other ER-resident molecular chaperones form heterocomplexes with each other and with collagen type IV chains.
Connect. Tissue Res.
33:265-273[Medline].
|
| 19.
|
Gage, P. J.,
M. Levine, and J. C. Glorioso.
1993.
Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B.
J. Virol.
67:2191-2201[Abstract/Free Full Text].
|
| 20.
|
Gilbert, R., and H. P. Ghosh.
1993.
Immunoelectron microscopic localization of herpes simplex virus glycoprotein gB in the nuclear envelope of infected cells.
Virus Res.
28:217-231[Medline].
|
| 21.
|
Gilbert, R.,
K. Ghosh,
L. Rasile, and H. P. Ghosh.
1994.
Membrane anchoring domain of herpes simplex virus glycoprotein gB is sufficient for nuclear envelope localization.
J. Virol.
68:2272-2285[Abstract/Free Full Text].
|
| 22.
|
Hammond, C., and A. Helenius.
1994.
Folding of VSV G protein: sequential interaction with BiP and calnexin.
Science
266:456-458[Abstract/Free Full Text].
|
| 22a.
|
Hammond, C., and A. Helenius.
1993.
A chaperone with a sweet tooth.
Curr. Biol.
3:884-885.
|
| 22b.
|
Hammond, C., and A. Helenius.
1995.
Quality control in the secretory pathway.
Curr. Biol.
7:523-529.
|
| 23.
|
Helenius, A.
1994.
How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum.
Mol. Biol. Cell
5:253-265[Medline].
|
| 24.
|
Herold, B. C.,
R. J. Visalli,
N. Sumarski,
C. Brandt, and P. G. Spear.
1994.
Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulfate and glycoprotein B.
J. Gen. Virol.
75:1211-1222[Abstract/Free Full Text].
|
| 25.
|
Herold, B. C.,
D. WuDunn,
N. Soltys, and P. G. Spear.
1991.
Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and infectivity.
J. Virol.
65:1090-1098[Abstract/Free Full Text].
|
| 26.
|
Highlander, S. L.,
W. F. Goins,
S. Person,
T. C. Holland,
M. Levine, and J. C. Glorioso.
1991.
Oligomer formation of the gB glycoprotein of herpes simplex virus type 1.
J. Virol.
65:4275-4283[Abstract/Free Full Text].
|
| 27.
|
Highlander, S. L.,
S. L. Sutherland,
P. J. Gage,
D. C. Johnson,
M. Levine, and J. C. Glorioso.
1987.
Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration.
J. Virol.
61:3356-3364[Abstract/Free Full Text].
|
| 28.
|
Ho, S. N.,
H. D. Hunt,
R. M. Horton,
J. K. Pellen, and L. R. Pease.
1989.
Site-directed mutagenesis by overlap extension using the polymerase chain reaction.
Gene
77:51-59[Medline].
|
| 29.
|
Hutchinson, L.,
H. Browne,
V. Wargent,
N. Davis-Poynter,
S. Primorac,
K. Goldsmith,
A. C. Minson, and D. C. Johnson.
1992.
A novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) and affects normal folding and surface expression of gH.
J. Virol.
66:2240-2250[Abstract/Free Full Text].
|
| 30.
|
Jackson, M. R.,
M. F. Cohen-Doyle,
P. A. Peterson, and D. B. Williams.
1994.
Regulation of MHC class I transport by the molecular chaperone, calnexin (p88, IP90).
Science
263:384-387[Abstract/Free Full Text].
|
| 31.
|
Johnson, D. C., and P. G. Spear.
1982.
Monensin inhibits the processing of herpes simplex virus glycoproteins, their transport to the cell surface, and the egress of virions from infected cells.
J. Virol.
43:1102-1112[Abstract/Free Full Text].
|
| 31a.
|
Kim, P. S., and P. Arvan.
1995.
Calnexin and BiP act as sequential molecular chaperones during thyroglobulin folding in the endoplasmic reticulum.
J. Cell Biol.
128:29-38[Abstract/Free Full Text].
|
| 32.
|
Kousoulas, K. G.,
D. J. Bzik,
N. DeLuca, and S. Person.
1983.
The effect of ammonium chloride and tunicamycin on the glycoprotein content and infectivity of herpes simplex virus type 1.
Virology
125:468-474[Medline].
|
| 33.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature (London)
277:680-685.
|
| 34.
|
Laquerre, S.,
S. Person, and J. C. Glorioso.
1996.
Glycoprotein B of herpes simplex virus type 1 oligomerizes through the intermolecular interaction of a 28-amino-acid domain.
J. Virol.
70:1640-1650[Abstract].
|
| 35.
|
Ligas, M. W., and D. C. Johnson.
1988.
A herpes simplex virus mutant in which glycoprotein D sequences are replaced by -galactosidase sequences binds to but is unable to penetrate into cells.
J. Virol.
62:1486-1494[Abstract/Free Full Text].
|
| 36.
|
Marlin, S. D.,
S. L. Highlander,
T. C. Holland,
M. Levine, and J. C. Glorioso.
1986.
Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.
J. Virol.
59:142-153[Abstract/Free Full Text].
|
| 37.
|
Marlin, S. D.,
T. C. Holland,
M. Levine, and J. C. Glorioso.
1985.
Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites.
J. Virol.
53:128-136[Abstract/Free Full Text].
|
| 38.
|
Navarro, D.,
P. Paz, and L. Pereira.
1992.
Domains of herpes simplex virus 1 glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion.
Virology
186:99-112[Medline].
|
| 39.
|
Norais, N.,
D. Tang,
S. Kaur,
S. H. Chamberlain,
F. R. Masiarz,
R. L. Burke, and F. Marcus.
1996.
Disulfide bonds of herpes simplex virus type 2 glycoprotein B.
J. Virol.
70:7379-7387[Abstract].
|
| 39a.
|
Otteken, A., and B. Moss.
1996.
Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin.
J. Biol. Chem.
271:97-103[Abstract/Free Full Text].
|
| 40.
|
Pellet, P. E.,
K. G. Kousoulas,
L. Pereira, and B. Roizman.
1985.
Anatomy of the herpes simplex virus 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants.
J. Virol.
53:243-253[Abstract/Free Full Text].
|
| 41.
|
Penfold, M. E. T.,
P. Armati, and A. L. Cunningham.
1994.
Axonal transport of herpes simplex virions to epidermal cells: evidence for a specialized mode of virus transport and assembly.
Proc. Natl. Acad. Sci. USA
91:6529-6533[Abstract/Free Full Text].
|
| 42.
|
Qadri, I.,
C. Gimeno,
D. Navarro, and L. Pereira.
1991.
Mutations in conformation-dependent domains of herpes simplex virus 1 glycoprotein B affect the antigenic properties, dimerization, and transport of the molecule.
Virology
180:135-152[Medline].
|
| 43.
|
Rasile, L.,
K. Ghosh,
K. Raviprakash, and H. P. Ghosh.
1993.
Effects of deletions in the carboxy-terminal hydrophobic region of herpes simplex virus glycoprotein gB on intracellular transport and membrane anchoring.
J. Virol.
67:4856-4866[Abstract/Free Full Text].
|
| 44.
|
Spear, P. G.
1993.
Membrane fusion induced by herpes simplex virus, p. 201-232.
In
J. Bentz (ed.), Viral fusion mechanisms. CRC Press, Boca Raton, Fla.
|
| 45.
|
Stackpole, C. W.
1969.
Herpes-type virus of the frog renal adenocarcinoma. I. Virus development in tumor transplants maintained at low temperature.
J. Virol.
4:75-93[Abstract/Free Full Text].
|
| 45a.
| Tatu, U., and A. Helenius. Interactions between
newly synthesized glycoproteins, calnexin and a network of
resident chaperones in the endoplasmic reticulum. J. Cell Biol.
136:555-565.
|
| 46.
|
Tengelson, L. A.,
N. E. Pederson,
P. R. Shaver,
M. W. Wathen, and F. L. Homa.
1993.
Herpes simplex virus type 1 DNA cleavage and encapsidation require the product of the UL28 gene: isolation and characterization of two UL28 deletion mutants.
J. Virol.
67:3470-3480[Abstract/Free Full Text].
|
| 47.
|
Torrisi, M. R.,
C. Di Lazzaro,
A. Pavan,
L. Pereira, and G. Campadelli-Fiume.
1992.
Herpes simplex virus envelopment and maturation studied by fracture label.
J. Virol.
66:554-561[Abstract/Free Full Text].
|
| 48.
|
Wada, I.,
D. Rindress,
P. H. Cameron,
W.-J. Ou,
J. J. Doherty II,
D. Louvard,
A. W. Bell,
D. Dignard,
D. Y. Thomas, and J. J. M. Bergeron.
1991.
Ssr and associated calnexin are major calcium binding proteins of the endoplasmic reticulum membrane.
J. Biol. Chem.
226:19599-19610.
|
| 49.
|
Wilson, I. A.,
H. L. Niman,
R. A. Houghten,
A. R., M. L. Connolly, and R. A. Lerner.
1984.
The structure of an antigenic determinant in a protein.
Cell
37:767-778[Medline].
|
| 50.
|
Yamashita, Y.,
K. Shimokata,
S. Mizuno,
T. Daikoku,
T. Tsurumi, and Y. Nishiyama.
1996.
Calnexin acts as a molecular chaperon during the folding of glycoprotein B of human cytomegalovirus.
J. Virol.
70:2237-2246[Abstract].
|
| 51.
|
Yamashita, Y.,
M. Yamada,
T. Daikoku,
H. Yamada,
A. Tadauchi,
T. Tsurumi, and Y. Nishiyama.
1996.
Calnexin associates with the precursors of glycoproteins B, C, and D of herpes simplex virus type 1.
Virology
225:216-222[Medline].
|
| 52.
|
Zheng, Z.,
E. Maidji,
S. Tugizov, and L. Pereira.
1996.
Mutations in the carboxyl-terminal hydrophobic sequence of human cytomegalovirus glycoprotein B alter transport and protein chaperone binding.
J. Virol.
70:8029-8040[Abstract].
|
J Virol, June 1998, p. 4940-4949, Vol. 72, No. 6
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Akkarawongsa, R., Pocaro, N. E., Case, G., Kolb, A. W., Brandt, C. R.
(2009). Multiple Peptides Homologous to Herpes Simplex Virus Type 1 Glycoprotein B Inhibit Viral Infection. Antimicrob. Agents Chemother.
53: 987-996
[Abstract]
[Full Text]
-
Britt, W. J., Jarvis, M. A., Drummond, D. D., Mach, M.
(2005). Antigenic Domain 1 Is Required for Oligomerization of Human Cytomegalovirus Glycoprotein B. J. Virol.
79: 4066-4079
[Abstract]
[Full Text]
-
Potel, C., Kaelin, K., Danglot, L., Triller, A., Vannier, C., Rozenberg, F.
(2003). Herpes simplex virus type 1 glycoprotein B sorting in hippocampal neurons. J. Gen. Virol.
84: 2613-2624
[Abstract]
[Full Text]
-
Wanas, E., Efler, S., Ghosh, K., Ghosh, H. P.
(1999). Mutations in the conserved carboxy-terminal hydrophobic region of glycoprotein gB affect infectivity of herpes simplex virus. J. Gen. Virol.
80: 3189-3198
[Abstract]
[Full Text]
-
Laquerre, S., Anderson, D. B., Stolz, D. B., Glorioso, J. C.
(1998). Recombinant Herpes Simplex Virus Type 1 Engineered for Targeted Binding to Erythropoietin Receptor-Bearing Cells. J. Virol.
72: 9683-9697
[Abstract]
[Full Text]